Celon Pharma 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Maciej Wieczorek

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Maciej Wieczorek

no data

테뉴어

Dr. Maciej Wieczorek, Ph D., served as Deputy Chairman of the Supervisory Board at Mabion S.A. and served as its Member of the Supervisory Board from February 16, 2017. Dr. Wieczorek has been President of...

Celon Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Recent updates

Second quarter 2024 earnings released: zł0.15 loss per share (vs zł0.18 profit in 2Q 2023)

New minor risk - Shareholder dilution

Celon Pharma S.A. Announces Strong Proof-Of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Oral Antipsychotic

Upcoming dividend of zł0.08 per share

Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl’ 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)

Full year 2023 earnings released: zł0.55 loss per share (vs zł0.77 loss in FY 2022)

Celon Pharma S.A. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released

Upcoming dividend of zł0.09 per share at 0.6% yield

Full year 2022 earnings released

Celon Pharma S.A. to Report Q3, 2023 Results on Nov 22, 2023

Third quarter 2022 earnings released

Second quarter 2022 earnings released

Upcoming dividend of zł0.29 per share

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

CEO

테뉴어